ReviewProbiotics and antimicrobial proteins2026
Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases, including metabolic-associated fatty liver disease (MAFLD), alcoholic liver disease (ALD), and viral hepatitis, are highly prevalent and constitute a major global health burden. Accumulating evidence indicates that dysbiosis of the gut microbiota is closely associated with the development and progression of various liver diseases. Among microbial regulators, Lactobacillaceae, a family of probiotic lactic acid bacteria, has attracted considerable attention for its capacity to reshape the gut microbiota, strengthen mucosal barrier integrity, modulate nutrient metabolism, and regulate both innate and adaptive immune responses. A growing body of evidence has shown that members of the Lactobacillaceae family can alleviate hepatic inflammation, reduce steatosis, and modulate gut-derived metabolic pathways involving bile acids, lactate, and short-chain fatty acids. This review provides a comprehensive overview of the role of Lactobacillaceae in acute and chronic liver diseases, examines the mechanisms by which this family influences liver diseases through the gut-liver axis, and highlights future directions for microbiota-based therapeutic strategies.
Indexed as
Identifiers
42217150What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.